Login to Your Account

Clinic Roundup

Thursday, April 21, 2011
Marina Biotech Inc., of Bothell, Wash., completed enrollment of its first cohort in its START-FAP Phase Ib/IIa trial of CEQ508, an attenuated bacteria engineered to deliver shRNA, for familial adenomatous polyposis. The cohort of three patients will receive the lowest dose as a daily drink for 28 days.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription